No price history available.
Key financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | IDRm | 277,398 | 630,530 | 715,425 | 702,068 | 1,920,812 | 2,760,422 | N/A | N/A |
| Operating profit | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | IDRm | 22,104 | 5,479 | 275,241 | -85,221 | -330,247 | -379,670 | N/A | N/A |
| EPS reported | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | IDRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | IDR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in IDR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
PT Pyridam Farma Tbk, an Indonesian-based enterprise, specializes in the development, production, and distribution of a broad spectrum of health-related products. Its offerings encompass pharmaceuticals, antibiotics, essential vitamins, dietary supplements, and traditional herbal remedies. The company's operations are divided into two main segments: Pharmaceutical Products and Contract Manufacturing Services, and Medical Device Products. Within its medical device division, the firm provides a variety of instruments and consumables. These include clinical waste management items, collection swabs and tubes, innerbox DCA, KF94 masks, parafilm, PCR extraction kits and their accompanying machinery, specimen bags, sterile containers, and tube stoppers. Furthermore, PT Pyridam Farma markets a diverse collection of skincare products, such as Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel. Its pharmaceutical portfolio addresses numerous therapeutic areas, including digestive and metabolic health, blood and blood-forming organ conditions, cardiovascular disorders, dermatological ailments, genitourinary system and sex hormone regulation, systemic corticosteroids, systemic antibacterial treatments, sensory organ issues, as well as musculoskeletal, nervous, and respiratory system conditions. Beyond medicinal lines, the company also develops and sells dietary supplements and preventive consumer health items, notably energy drinks and various healthy ready-to-consume beverages. A key area of its strategic focus involves conducting extensive research and development in biotechnology, life sciences, and medical science. Established in 1976, PT Pyridam Farma Tbk is headquartered in Jakarta, Indonesia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
PT Pyridam Farma Tbk, an Indonesian-based enterprise, specializes in the development, production, and distribution of a broad spectrum of health-related products. Its offerings encompass pharmaceuticals, antibiotics, essential vitamins, dietary supplements, and traditional herbal remedies. The company's operations are divided into two main segments: Pharmaceutical Products and Contract Manufacturing Services, and Medical Device Products. Within its medical device division, the firm provides a variety of instruments and consumables. These include clinical waste management items, collection swabs and tubes, innerbox DCA, KF94 masks, parafilm, PCR extraction kits and their accompanying machinery, specimen bags, sterile containers, and tube stoppers. Furthermore, PT Pyridam Farma markets a diverse collection of skincare products, such as Arosa gel, A-Stark Gel, Hymen gel, Pyderen Emulsion, Tonic Bust Emulsion, Calmosan Cream, and Di-Herb gel. Its pharmaceutical portfolio addresses numerous therapeutic areas, including digestive and metabolic health, blood and blood-forming organ conditions, cardiovascular disorders, dermatological ailments, genitourinary system and sex hormone regulation, systemic corticosteroids, systemic antibacterial treatments, sensory organ issues, as well as musculoskeletal, nervous, and respiratory system conditions. Beyond medicinal lines, the company also develops and sells dietary supplements and preventive consumer health items, notably energy drinks and various healthy ready-to-consume beverages. A key area of its strategic focus involves conducting extensive research and development in biotechnology, life sciences, and medical science. Established in 1976, PT Pyridam Farma Tbk is headquartered in Jakarta, Indonesia.